Literature DB >> 18589864

Animal models of cancer pain.

Cholawat Pacharinsak1, Alvin Beitz.   

Abstract

Modern cancer therapies have significantly increased patient survival rates in both human and veterinary medicine. Since cancer patients live longer they now face new challenges resulting from severe, chronic tumor-induced pain. Unrelieved cancer pain significantly decreases the quality of life of such patients; thus the goal of pain management is to not only to alleviate pain, but also to maintain the patient's physiological and psychological well-being. The major impediment for developing new treatments for cancer pain has been our limited knowledge of the basic mechanisms that drive cancer pain and the lack of adequate animal cancer pain models to study the molecular, biochemical and neurobiological pathways that generate and maintain cancer pain. However this situation has recently changed with the recent development of several novel animal models of cancer pain. This review will focus on describing these animal models, many of them in rodents, and reviewing some of the recent information gained from the use of these models to investigate the basic mechanims that underlie the development and maintenance of cancer pain. Animal models of cancer pain can be divided into the following five categories: bone cancer pain models, non-bone cancer pain models, cancer invasion pain models, cancer chemotherapeutic-induced peripheral neuropathy models, and spontaneous occurring cancer pain models. These models will be important not only for enhancing our knowledge of how cancer pain is generated, but more importantly for the development of novel therapeutic regimes to treat cancer pain in both domestic animals and humans.

Entities:  

Mesh:

Year:  2008        PMID: 18589864      PMCID: PMC2704117     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  187 in total

Review 1.  What should we be measuring in behavioral studies of chronic pain in animals?

Authors:  Jeffrey S Mogil; Sara E Crager
Journal:  Pain       Date:  2004-11       Impact factor: 6.961

2.  Development and validation of a new model of inflammation in the cat and selection of surrogate endpoints for testing anti-inflammatory drugs.

Authors:  J M Giraudel; A Diquelou; P Lees; P L Toutain
Journal:  J Vet Pharmacol Ther       Date:  2005-06       Impact factor: 1.786

Review 3.  Bone cancer pain and the role of RANKL/OPG.

Authors:  D R Clohisy; P W Mantyh
Journal:  J Musculoskelet Neuronal Interact       Date:  2004-09       Impact factor: 2.041

4.  Utility of decompressive surgery in the prophylaxis and treatment of cisplatin neuropathy in adult rats.

Authors:  P Tassler; A L Dellon; G J Lesser; S Grossman
Journal:  J Reconstr Microsurg       Date:  2000-08       Impact factor: 2.873

Review 5.  Controlling the pain of cancer.

Authors:  K M Foley
Journal:  Sci Am       Date:  1996-09       Impact factor: 2.142

6.  Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model.

Authors:  Dorothy Cimino Brown; Michael J Iadarola; Sandra Z Perkowski; Hardam Erin; Frances Shofer; Karai J Laszlo; Zoltan Olah; Andrew J Mannes
Journal:  Anesthesiology       Date:  2005-11       Impact factor: 7.892

7.  Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs.

Authors:  B KuKanich; B D X Lascelles; M G Papich
Journal:  J Vet Pharmacol Ther       Date:  2005-08       Impact factor: 1.786

Review 8.  Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

Authors:  Julie M Blair; Hong Zhou; Markus J Seibel; Colin R Dunstan
Journal:  Nat Clin Pract Oncol       Date:  2006-01

9.  Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling.

Authors:  Elizabeth S McDonald; Anthony J Windebank
Journal:  Neurobiol Dis       Date:  2002-03       Impact factor: 5.996

10.  The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Authors:  Knut Liepe; Roswitha Runge; Jörg Kotzerke
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-22       Impact factor: 4.553

View more
  37 in total

Review 1.  Translational approaches to treatment-induced symptoms in cancer patients.

Authors:  Robert Dantzer; Mary W Meagher; Charles S Cleeland
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

2.  Pain management standards in the eighth edition of the Guide for the Care and Use of Laboratory Animals.

Authors:  Larry Carbone
Journal:  J Am Assoc Lab Anim Sci       Date:  2012-05       Impact factor: 1.232

3.  Cancer pain--progress and ongoing issues in the United States.

Authors:  Shalini Dalal; Eduardo Bruera
Journal:  Pain Res Manag       Date:  2009 Sep-Oct       Impact factor: 3.037

Review 4.  Predictive validity of behavioural animal models for chronic pain.

Authors:  Odd-Geir Berge
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  Grid-climbing Behaviour as a Pain Measure for Cancer-induced Bone Pain and Neuropathic Pain.

Authors:  Sarah Falk; Simone Gallego-Pedersen; Nicolas C Petersen
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

6.  Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain.

Authors:  Juan Miguel Jimenez-Andrade; Joseph R Ghilardi; Gabriela Castañeda-Corral; Michael A Kuskowski; Patrick W Mantyh
Journal:  Pain       Date:  2011-09-09       Impact factor: 6.961

Review 7.  Animal models of chemotherapy-evoked painful peripheral neuropathies.

Authors:  Nicolas Authier; David Balayssac; Fabien Marchand; Bing Ling; Aude Zangarelli; Juliette Descoeur; François Coudore; Emmanuel Bourinet; Alain Eschalier
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

8.  Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior.

Authors:  Gail Pereira Do Carmo; Glenn W Stevenson; William A Carlezon; S Stevens Negus
Journal:  Pain       Date:  2009-05-10       Impact factor: 6.961

Review 9.  The application of conditioning paradigms in the measurement of pain.

Authors:  Jun-Xu Li
Journal:  Eur J Pharmacol       Date:  2013-03-13       Impact factor: 4.432

10.  Implementation of Humane Endpoints in a Urinary Bladder Carcinogenesis Study in Rats.

Authors:  Mónica Oliveira; Elisabete Nascimento-Gonçalves; Jessica Silva; Paula A Oliveira; Rita Ferreira; Luís Antunes; Regina Arantes-Rodrigues; Ana I Faustino-Rocha
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.